Pfizer (PFE)
(Delayed Data from NYSE)
$28.94 USD
-0.15 (-0.52%)
Updated Sep 30, 2024 04:00 PM ET
After-Market: $28.91 -0.03 (-0.10%) 7:26 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.94 USD
-0.15 (-0.52%)
Updated Sep 30, 2024 04:00 PM ET
After-Market: $28.91 -0.03 (-0.10%) 7:26 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Stock Market News for Nov 2, 2022
by Zacks Equity Research
U.S. stocks ended lower for the second-straight session on Tuesday as better-than-expected economic data dimmed hopes of the Fed signaling a slower pace of interest rate hikes in the future after it announces another massive rate hike at the end of its two-day policy meeting starting on Wednesday.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.
Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading
Pre-Markets in Green to Start a Fresh Month
by Zacks Equity Research
Pre-Markets in Green to Start a Fresh Month
Pre-Markets Up Ahead of New Fed Hike, Q3 Beats
by Mark Vickery
Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).
Pfizer (PFE) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 21.09% and 7.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dow Notches Strongest Month of Trading Since 1976
by Mark Vickery
At +11%, it's the best October on record for the blue-chip index and the strongest single-month of trading since the U.S. Bicentennial.
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AbbVie (ABBV) Q3 Earnings Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 2.81% and 0.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer Earnings Preview: Growth & Diversification is Key
by Shaun Pruitt
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
by Zacks Equity Research
Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $45.54 in the latest trading session, marking a +1.31% move from the prior day.
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.
Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab
by Zacks Equity Research
Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $43.65, moving +1.84% from the previous trading session.
These 3 Cash-Generating Machines Pay Investors Nicely
by Derek Lewis
In a historically-volatile year in the market so far in 2022, dividends have been a significant perk, helping to shield investors from drawdowns.